| Autor: |
Amancherla K; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: kaushik.amancherla@vumc.org., Schlendorf KH; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Vlasschaert C; Department of Medicine, Queen's University, Kingston, Ontario, Canada., Lowery BD; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee., Wells QS; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee., See SB; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York., Zorn E; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York., Colombo PC; Division of Cardiology, Columbia University Medical Center, New York, New York., Reilly MP; Division of Cardiology, Columbia University Medical Center, New York, New York., Lindenfeld J; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Uriel N; Division of Cardiology, Columbia University Medical Center, New York, New York., Shah RV; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Freedman JE; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Moslehi J; Section of Cardio-Oncology and Immunology (JM), University of California San Francisco, San Francisco, California., Bick AG; Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Clerkin K; Division of Cardiology, Columbia University Medical Center, New York, New York. |
| Abstrakt: |
Competing Interests: Declaration of competing interest Dr. Bick is on the scientific advisory board of TenSixteen Bio. Dr. Moslehi has served on advisory boards for Bristol Myers Squibb, AstraZeneca, Myovant, Cytokinetics, Takeda, BeiGene, Kiniksa, Kurome Therapeutics, and Pfizer. All other authors declare no relevant conflicts of interest. In the past 24 months, Dr. Shah has served as a consultant for Myokardia, Cytokinetics, and Best Doctors, and has been on a scientific advisory board for Amgen. Dr. Shah is a co-inventor on a patent for ex-RNAs signatures of cardiac remodeling. |
Full Text from ScienceDirect